Pembrolizumab for treatment-related neuroendocrine prostate carcinoma with a high tumor mutational burden: a case report

Pembrolizumab for treatment-related neuroendocrine prostate carcinoma with a high tumor mutational burden: a case report

Pembrolizumab has emerged as a significant therapeutic option for the treatment of solid tumors with a high tumor mutational burden (TMB-high). However, there have been no reports of its use in treatment-related neuroendocrine prostate carcinoma (t-NEPC) with TMB-high. We present the case of a 66-ye...

Full description

Saved in:
Bibliographic Details
Main Authors: Keiji Shiba, Motohiro Fujiwara, Ayaka Onuki, Daisuke Kato, Takeshi Shirakawa, Yohei Shimizu, Takumasa Amemiya, Tsunehiro Nenohi, Yuki Matsumoto, Masayasu Urushibara, Hideto Kano, Kazuhiro Ishizaka, Mikiko Takahashi, Minato Yokoyama
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Oncology
Subjects:
pembrolizumab
prostate cancer
tumor mutational burden
treatment-related neuroendocrine prostate carcinoma
immune checkpoint inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1642412/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1642412/full

Similar Items